A detailed history of Janus Henderson Group PLC transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, Janus Henderson Group PLC holds 51,700 shares of WVE stock, worth $737,242. This represents 0.0% of its overall portfolio holdings.

Number of Shares
51,700
Previous 51,700 -0.0%
Holding current value
$737,242
Previous $257,000 64.59%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.38 - $6.48 $226,446 - $335,016
51,700 New
51,700 $257,000
Q1 2020

May 14, 2020

SELL
$6.94 - $14.22 $5.57 Million - $11.4 Million
-802,742 Closed
0 $0
Q4 2019

Feb 18, 2020

SELL
$7.99 - $37.6 $26.2 Million - $123 Million
-3,274,718 Reduced 80.31%
802,742 $6.43 Million
Q3 2019

Nov 14, 2019

BUY
$19.17 - $27.4 $13.1 Million - $18.8 Million
685,162 Added 20.2%
4,077,460 $83.7 Million
Q2 2019

Jul 31, 2019

BUY
$22.93 - $42.84 $10.8 Million - $20.2 Million
470,402 Added 16.1%
3,392,298 $88.5 Million
Q1 2019

Apr 30, 2019

BUY
$32.69 - $47.91 $41.9 Million - $61.4 Million
1,280,702 Added 78.03%
2,921,896 $114 Million
Q4 2018

Feb 06, 2019

BUY
$37.1 - $50.11 $4.62 Million - $6.23 Million
124,414 Added 8.2%
1,641,194 $69 Million
Q3 2018

Nov 09, 2018

SELL
$36.35 - $55.2 $71,900 - $109,185
-1,978 Reduced 0.13%
1,516,780 $75.8 Million
Q2 2018

Aug 10, 2018

BUY
$33.85 - $50.65 $5.43 Million - $8.13 Million
160,545 Added 11.82%
1,518,758 $58.1 Million
Q1 2018

May 14, 2018

BUY
$32.45 - $54.7 $21.1 Million - $35.5 Million
648,989 Added 91.51%
1,358,213 $54.5 Million
Q4 2017

Feb 09, 2018

BUY
$21.8 - $39.35 $15.5 Million - $27.9 Million
709,224
709,224 $24.9 Million

Others Institutions Holding WVE

About Wave Life Sciences Ltd.


  • Ticker WVE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,820,096
  • Market Cap $1.24B
  • Description
  • Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...
More about WVE
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.